|Institutional Source||Beutler Lab|
|Gene Name||prostaglandin I receptor (IP)|
|Synonyms||IP, prostacyclin receptor|
|Is this an essential gene?||Probably non essential (E-score: 0.079)|
|Stock #||R7311 (G1)|
|Chromosomal Location||16906490-16910905 bp(+) (GRCm38)|
|Type of Mutation||missense|
|DNA Base Change (assembly)||T to A at 16907048 bp|
|Amino Acid Change||Aspartic acid to Glutamic Acid at position 88 (D88E)|
|Ref Sequence||ENSEMBL: ENSMUSP00000122080 (fasta)|
|Gene Model||predicted gene model for transcript(s): [ENSMUST00000086101] [ENSMUST00000144408]|
|PDB Structure||Molecular analysis of the interaction between the prostacyclin receptor and the first PDZ domain of PDZK1 [X-RAY DIFFRACTION]|
|Predicted Effect||probably benign
|Predicted Effect||probably damaging
AA Change: D88E
PolyPhen 2 Score 1.000 (Sensitivity: 0.00; Specificity: 1.00)
AA Change: D88E
|Coding Region Coverage||
FUNCTION: [Summary is not available for the mouse gene. This summary is for the human ortholog.] The protein encoded by this gene is a member of the G-protein coupled receptor family 1 and has been shown to be a receptor for prostacyclin. Prostacyclin, the major product of cyclooxygenase in macrovascular endothelium, elicits a potent vasodilation and inhibition of platelet aggregation through binding to this receptor. [provided by RefSeq, Jul 2008]
PHENOTYPE: Homozygotes for a targeted null mutation exhibit increased susceptibility to thrombosis and injury-induced vascular proliferation, and decreased inflammatory and pain responses. [provided by MGI curators]
|Allele List at MGI|
|Other mutations in this stock||
|Other mutations in Ptgir||
(F):5'- TATGAAGATGATGGCCAGCG -3'
(R):5'- TCCACAGCCATGGCAAAGAG -3'
(F):5'- AGCGATGGACATCCTGGAC -3'
(R):5'- CCATGGCAAAGAGGATGAGC -3'